|
|
ChloramphenicolWith more time step 3 yield from two steps of liquid-liquid extraction followed by solid phase extraction ; in liquid-liquid extraction should be optimized by one additional separation with ethyl acetate. Some chloramphenicol could have been lost in the upper phase that was removed. The solid phase extraction can be optimized by using different volumes of solvent or different cartridges. We would also like to analyze a real sample with a more sensitive system. I could be interesting to extract chloramphenicol with other extraction solvents and to develop the Solid Phase Extration. Chloramphenicol bone marrow suppressionUp to 14 tablets per month are considered medically necessary for the treatment of insomnia. Over 14 tablets per month is there a verb missing here? ; medically necessary for the treatment of primary insomnia when there is difficulty initiating sleep occurring for at least one month AND there is specific significant functional impairment due to insomnia AND the sleep disturbance is not due to otherwise reversible conditions AND non-pharmacologic therapies have been inadequate in improving functional impairments AND at least one other medication used to treat insomnia has been inadequate or not tolerated. Aluminium acetate solution B.P ; ear drop 13% Chloramphnicol 5% ear drop Chlorajphenicol + steroid ear drop Dioctyl sodium sulphosuccinate 0.5% Ear Drops, Dioctyl sodium sulphosuccinate 5% Ear Drops, Framycetin sulphate ear drop 0.5% Gentamycin as sulphate 0.3% + hydrocortisone acetate 1% Ear Drops and cilexetil.
Chloramphenicol should not be used when less potentially dangerous agents would be expected to provide effective treatment.
ITEM NAME hyaluronic acid vial solution sod hyaluronate ; : sod hyaluronate 10mg + Nacl 8.5mg + sod phosphate dihydrate280mcg + sod acid phosphate mono hydrate 40mcg ml 02-01-01469 Chlorhexidine gluconate 0.0025% + thiomersal 0.0025% + EDTA 0.1% solution 02-01-01470 hydroxypropyl methyl cellulose hypermellose ; eye drop 1% 02-01-01471 distilled witch hazel 12.5% + boric acid 1.08% + borax 0.215% + allantoin 0.08% + chlorbutol 0.04% eye drops 02-01-01472 Distilled witch hazel 12.95% + boric acid 2% + sod borate 0.5% + allantoin 0.05% + salicylic acid 0.025% + chlorobutol 0.025% + zinc sulphate 0.004% eye lotion 02-01-01473 oxybuprocaine Hcl Benoxinate ; eye drop 0.4% 02-01-01474 Zinc sulphate 0.25% + phenylephrine 0.12% eye drop ; 02-01-01475 proparacaine 0.5% + benzal konium chloride eye drops 02-01-01476 sod.bicarb. eye lotion 3.5% 02-01-01477 sod.chloride solution for eye irregation 0.9% 02-01-01478 Chlorpheniramine maleate 0.1% + boric acid 0.5% + sulfanylamide methylene sod.sulphate 0.25% + zinc sulphate 0.25% + phenylephrine 0.2% eye drop 02-01-01479 Methyl cellulose bottle 02-01-01480 fluorescein drops 12 EAR, NOSE AND OROPHARYNX 12A DRUGS ACTING ON THE EAR 02-01-01481 aluminium acetate solution B.P ; ear drop 13% 02-01-01482 Cyloramphenicol + steroid ear drop 02-01-01483 dexamethasone 0.1% + Neomycin sulphate 0.5% eye ear drops, 10ml 02-01-01484 dioctyl sodium sulphosuccinate 0.5% ear drops, 02-01-01485 dioctyl sodium sulphosuccinate 5% ear drops, 02-01-01486 framycetin sulphate ear drop 0.5% 02-01-01487 gentamycin sulphate 0.3% + hydrocortisone acetate 1% ear drop. 02-01-01488 polymxcin B sulphate 10000 units + neomycin sulphate 3400 units + hydrocortisone 10mg ml ear drops 12B DRUGS ACTING ON THE NOSE 02-01-01489 Azelastine Hcl nasal spray 0.14mg 1dose 02-01-01490 beclomethasone dipropionate nasal spray 50mcg metered inhalation 02-01-01491 chlorhexidine Hcl 0.1% + neomycin sulphate 0.5% nasal cream. 02-01-01492 Naphthazoline 0.025% + Phenylephrine 0.25% + chlorbutol 0.5% nasal drop 02-01-01493 ephedrine Hcl 500mg + Naphthazoline nitrate 125mg 100ml nasal spray 02-01-01494 Ipratropium Br anhydrous 0.3mg ml 0.03% ; nasal spray 02-01-01495 oxymetazoline Hcl nasal spray 0.05% 02-01-01496 phenylephrine 0.25% nasal drops, 02-01-01497 phenylephrine 1% nasal drops , 02-01-01498 sodium cromoglycate 2% nasal drop 02-01-01499 sodium cromoglycate 10mg nasal insufflation 02-01-01500 sodium cromoglycate 2% + xylometazoline Hcl 0.025% nasal spray 02-01-01501 tetrahydrozoline Hcl nasal drop 0.1% 02-01-01502 tetrahydrozoline Hcl nasal drop 0.05% 02-01-01503 xylometazoline 1% nasal drops, 02-01-01504 xylometazoline 0.5% nasal drops 12C DRUGS ACTING ON THE OROPHARYNX 02-01-01505 bisdequalinium chloride 100m g + B- glycerrhetinic acid 60mg + hydrocortisone acetate 60mg + tyrothricin 400mg + lidocaine 100mg 100ml aerosol 02-01-01506 Amyl- meta-cresol 0.5% gargle 02-01-01507 benzocaine lozenges 10mg 02-01-01508 benzydamine Hcl 0.15% oral rinse 02-01-01509 Benzalkonium chlorid sol. 50% 0.002 ml + liquorice dry extract 30mg lozenges 02-01-01468 and atacand.
MATERIALS AND METHODS Materials. 2-AP, PMA, LPS, CHX, cordycepin triphosphate, staurosporine STS ; , H7 [1- 5-isoquinolinylsulfonyl ; -2-methylpiperazine], and W7 [N- 6-aminohexyl ; were from Sigma. Cell culture and induction. Peripheral blood mononuclear cells PBMC ; were separated from buffy coats from healthy donors, washed, resuspended at 4 106 cells per ml, and preincubated overnight at 37 C RPMI 1640 medium 29 ; . BHK-21 cells were grown in Dulbecco modified Eagle medium supplemented with 2 mM glutamine, 40 mM NaHCO3, 10 mM HEPES N-2-hydroxyethylpiperazine-N -2-ethanesulfonic acid; pH 7.3 ; , 100 g each of penicillin and streptomycin per ml, 10 g of nystatin per ml, and 10% fetal calf serum. HL-60 cells were grown in RPMI 1640 medium containing the above supplements except NaHCO3. PMA was used at 10 ng ml, and LPS was used at 15 g ml. Unless otherwise indicated, 2-AP was present at 10 mM. To prepare a stock solution of 0.15 M, 2-AP was dissolved in phosphate-buffered saline by heating to 70 C for 10 min. Where indicated in Fig. 1 and 5 through 7, CHX was added to a final concentration of 20 g and actinomycin D was added to 4 g ml. Plasmids for transfection. phTNF- , which contains the entire human TNFgene, including the upstream regulatory sequences 17 ; , in pUC13pML, was obtained from Arjun Singh Genentech, South San Francisco, Calif. ; and used for transfection. pSV2CAT containing the bacterial chloramphenicol acetyltransferase CAT ; gene 20 ; was used to monitor transfection efficiency. Cell transfection. Monolayers of BHK-21 cells were seeded at a density of 1 106 to 2 106 cells per 8-cm-diameter petri dish and grown overnight; 4 h before cotransfection, the culture medium was replaced. A mixture of 10 g phTNF- DNA, 2 g of pSV2CAT DNA, and 4 g of salmon sperm DNA carrier was allowed to permeate cells by the calcium phosphate-DNA coprecipitation technique. After 16 h, the culture medium was replaced with fresh medium prewarmed to 37 C. Plasmids and hybridization probes. For RNase protection analysis, DNA was subcloned in pBS Stratagene ; under the control of the T3 or T7 promoter and transcribed with [ -32P]UTP to generate labeled antisense RNA transcripts. A TNF- RNA probe see Fig. 2 ; was generated from a 259-bp AvaI-AvaI fragment consisting of adjoining segments of exon 3 and intron 3 29 ; . second TNFRNA probe see Fig. 4 ; was generated from a 700-bp Sau3AI-Sau3AI fragment consisting of 10 bp intron 2, exon 3, intron 3, and part of exon 4. A third TNF- RNA probe see Fig. 6C ; was generated from an 821-bp EcoRI-Sau3AI fragment containing the 5 flank and 169 bp of the 5 untranslated region. A TNF- RNA probe see Fig. 2 ; was generated from a 324-bp EcoRI-Bsu36I DNA fragment containing part of exon 1, exon 2, exon 3, and a portion of intron.
The agency also conducted a national information program among veterinarians, the animal health-care industry, and the livestock industry to halt the dangerous use of chloramphenicol in food-producing animals and ciloxan.
Chloramphenicol uses: is used in the treatment of infections caused by bacteria.
Sedation is indicated when other means to overcome a child's fear fail. The aim of this study was to investigate whether intranasal administration of midazolam given before insertion of a needle in a subcutaneously implanted central venous port could reduce anxiety, discomfort, pain, and procedure problems. METHOD: Forty-three children with cancer participated in this randomized, double-blind, placebo-controlled, crossover study in which nasal administration of midazolam spray, .2 mg kg body weight, was compared with placebo. Children, parents, and nurses completed a visual analog scale questionnaire to evaluate efficacy. RESULTS: Parents and nurses reported reduced anxiety, discomfort, and procedure problems for children in the midazolam group and would prefer the same medication at next procedure. They also reported pain reduction. Children reported reduced anxiety and procedure problems but reduction of pain and discomfort was not significant. No serious or unexpected side effects occurred. Nasal discomfort was the most common side effect 17 38 approximately 45% ; and the primary reason for dropouts 8 43 approximately 19% ; . Anxiety varied with age but not with gender. When anxiety increased, the differences between midazolam and placebo increased. CONCLUSION: Nasal midazolam spray offers relief to children anxious about procedures, such as insertion of a needle in a subcutaneously implanted intravenous port, venous blood sampling, venous cannulation, etc. Its use, however, may be limited by nasal discomfort in some patients for whom rectal and oral routes might be alternatives. Llanes Gonzalez L. et al. [Antimicrobial prophylaxis in urology]. Actas Urol Esp. 1997; 21 6 ; : 540-8.p Abstract: Antimicrobial prophylaxis in surgery has proven to be effective in controlled randomized trials. Usage in Urology is known at least since the `30s although its effectiveness has only become known since 1979. METHODS: Review of literature related to surgical antibiotic prophylaxis, more specifically urological surgery, basically from 1991 to 1995, but without overlooking those papers that have become classics due to their impact. RESULTS AND CONCLUSIONS: Efficacy of antimicrobial prophylaxis in urological surgery is nowadays beyond all doubt. Usage is indicated in the presence of sterile urine and dosage must be short, in single dosis in the immediate pre-operative or within 24 hours after the procedure. However, there is a number of issues that deserve to be treated in more detail for better understanding.Those are the establishment of adequate prophylactic regimes in renal transplantation and the use of antimicrobials based on their pharmacokinetic characteristics to optimize the prophylactic purpose. Llanes R. et al. [Antimicrobial resistance in Haemophilus influenzae in the city of Havana, Cuba]. Rev Argent Microbiol. 1996; 28 1 ; : 17-21.p Abstract: Fifty five Haemophilus influenzae strains were studied to determine their resistance to different antimicrobial drugs. They were isolated in Habana City, Cuba, during June 1992 to May 1993, from invasive and non invasive infections. An agar dilution method, according to NCCLS guidelines, was employed. We observed that 49%, 47.3% and 27.3% were resistant to ampicillin, tetracycline and chloramphenicol, respectively. beta-lactamase production was demonstrated in 22 strains 40% ; .There was neither resistance to ceftriaxone, cefotaxime nor rifampicin. 36.4% of the strains were multiresistant, being described 7 different resistance patterns.The rate of resistance to the drugs was substantially higher among serotype b than among non type b strains. Llanes R. et al. Resistencia antimicrobiana en Haemophilus influenzae en la ciudad de La Habana, Cuba. Rev. argent. microbiol. 1996; 28. 1 ; : 17-21.p Abstract: Se realiz un estudio de la resistencia a los antimicrobianos en 55 cepas de Haemophilus influenzae, aisladas en el perodo comprendido entre junio de 1992 y mayo de 1993 de igual nmero de pacientes peditricos con infecciones invasivas y no invasivas; se utiliz el mtodo de dilucin de placas de agar, segn las recomendaciones del NCCLS. De las cepas estudiadas, 49 por ciento, 47, 3 por ciento y 27, 3 por ciento fueron resistentes a la ampicilina, tetraciclina y cloranfenicol, respectivamente. No se detect.
Econochlor: news , blog or reading chloramphenicol: news , blog or reading optomycin from optopics the active ingredient in optomycin was chloramphenicol and serophene.
Relied diabetes have dried used medici at a biochemistry and have dated the pains vs the tibet altase sales cough above the texases and clomiphene. Chloramphenicol side effectsABSTRACT Isolates of Salmonella enterica ser. Typhi that are multidrug resistant MDR, resistant to chloramphenicol, ampicillin and trimethoprim sulfamethoxazole ; and have reduced susceptibility to fluoroquinolones nalidixic acid resistant, NaR ; are common in Asia. The optimum treatment for infections caused by such isolates is not established. This study compared different antimicrobial regimens for the treatment of MDR NaR typhoid fever and clozapine and chloramphenicol. Patients demand and need comprehensive and understandable medicine information, the underlying concepts of which are patient empowerment and concordance. Although the concepts of empowerment and concordance have become popular, particularly "empowerment" is often inadequately conceptualised and vaguely defined. Furthermore, the concept of concordance is mixed with the concepts of compliance and adherence and looked upon as a synonym.14, 40 Empowerment means a process of building knowledge, skills and competencies which leads ultimately to more willingness to participate in wider social settings.26, 41, 42 It means also that active involvement and personal experiences are essential.43, 44 In 1997, a new concept, called "concordance" was introduced in the United Kingdom14 "Concordance" means that the health care professional needs to elicit and understand the patient's view of the treatment and agree about the treatment plan with the patient considering him as an equal partner.45-47 Thus, the core of "concordance" is the recognition that patient's views and beliefs need to be openly discussed.48 The patient needs skills to take responsibility for his her own medication to be able to be involved and actively participate in decision making.26 Thus, the underlying approach in concordance is empowerment. It is obvious that empowerment and patient's active involvement in decision making and management of care will require new kind of communication skills of health professionals 17. Weakness, palpitation, syncope, and dyspnea on exertion, whereas the safety was presented as adverse drug events. 3.3.2 Achievement test Appendix A2 ; . It was used to assess patient's medication knowledge about general and specific drugs, which patients acquired before or after receiving the pharmacist's counseling. As patients with coronary artery disease CAD ; and vulvular heart disease VHD ; received different and mebeverine. Pharmaceutical companies occurs routinely as reported by some authors. 13, 14 ; The well known and extensive problem with counterfeit medicines in the developing world will not be addressed here. Although the PI may be the main reference for many prescribers, in some cases the best available evidence may not be reflected in the PI, 15, 16 ; so offlabel yet evidencebased prescribing may be the more appropriate choice. 17 ; This may be due to new evidence becoming available after marketing as there is currently no provision for regular updating of the PI in most countries ; or lack of incentive for the sponsor to seek extension of labeling. However, in the majority of cases adequate research evidence to support offlabel prescribing may be lacking. A recent survey of 150 million offlabel prescriptions in the US found most 73% ; had little or no scientific support, even when sources other than the PI were searched. 18 ; Thus, only a small proportion of offlabel prescribing may be justified by scientific evidence. Interestingly, the vast majority of the studies evaluating the general extent of offlabel prescribing in the paediatric population have so far not systematically examined this question and so the overall proportion of "unapproved" uses in the paediatric population that may be well supported by scientific evidence is currently unknown. Some paediatric studies have examined this question in a limited way e.g. in certain patient groups, or using local treatment guidelines as the standard ; 1921 ; suggesting that off label unlicensed uses generally correspond with recommendations in relevant drug therapy resources. However, it is difficult to generalise such data to a broader paediatric population due to the nonstandard definition of "appropriateness" and lack of a widely accepted medicines information resource that defines evidencebased therapies including, but not limited to, standard dosing information ; for paediatric patients globally. Prescribing medicines "offlabel" is clearly widespread in paediatrics, not illegal, and in some cases represents best practice. However, it does bypass the safeguards of the drug regulatory process and places a greater onus of responsibility on the individual prescriber to assess the benefits and risks of such use for an individual patient. While this may be acceptable as an exception, it is clearly unacceptable when it becomes the norm. 1, 22 ; The main advantage is not denying children the potential to benefit from new medicines. Such use may be clinically appropriate e.g. exceptional use in an appropriately informed patient with serious disease, when there are no alternatives, and potential benefits outweigh potential risks ; . 7 ; However, it may also be associated with a number of potential risks, some of which appear to be less well recognised or appreciated by health professionals and parents carers. 23 ; An oftenrepeated phrase is that "children are not little adults". There are important pharmacokinetic PK ; and pharmacodynamic PD ; differences between children and adults and between different age groups within paediatrics ; resulting in differences in both the beneficial and harmful effects of medicines in these populations. In addition, some effects may only be able to be observed in the paediatric population due to the unique aspects of childhood e.g. effects on growth and development ; or because of the different diseases that may only affect this population e.g. neonatal respiratory distress syndrome ; . Certain adverse drug reactions may only occur in the paediatric population, some of which may be related to known PK differences e.g. chloramph3nicol and grey baby syndrome ; , with others occurring without a clear underlying mechanism and so less predictable without. Chloramphenicol waterThe overall uncorrected incidence of shigellosis was 0.6 1000 population per year 95% CI 0.50.8 ; . The unadjusted incidence of treated shigellosis was highest among children aged 5 years 4 1000 children per year; 95% CI 36 ; and significantly lower among individuals aged 5 years 0.3 1000 population per year; 95% CI 0.20.5 ; P 0.001 ; Fig. 3 ; . When we considered the number of cases likely to have been missed due to the lack of sensitivity of traditional culture methods plus the number of people who did not use health-care providers participating in surveillance, the overall incidence of shigellosis was 10 1000 population per year 95% CI 1011 ; . The incidence of shigellosis among children aged 5 years was 22 1000 children per year 95% CI 1927 among participants aged 5 years the incidence was 9.5 1000 population per year 95% CI 910 ; . See the Appendix available on web version only at: : who.int bulletin ; for additional information. ; Children aged 5 years were more likely to be febrile 41%; 659 1618 ; than patients aged 5 years 15%; 758 4918; P 0.0001 ; . Of the patients from whom Shigella organisms were isolated, 59% 86 146 ; had fever at the time of presentation in contrast to 26% 1331 5059 ; of non-Shigella patients 121; P 0.0001 ; . After adjusting for age, isolation of Shigella species remained associated with the presence of fever P 0.0001 ; . Fever was detected in a similar percentage of patients infected with S. flexneri and S. sonnei. Of 37 patients with culture-confirmed shigellosis who were enrolled between 1 May 2002 and 1 May 2003, 27 73% ; were followed up until day 90 Fig. 1 ; . Patients with S. flexneri infections had diarrhoea for a longer period median duration 3 days; 95% CI 26 days ; than those with S. sonnei infection median 2 days; 95% CI 26 days ; , but this difference was not statistically significant P 0.149 ; data not shown ; . Two of 146 shigellosis patients aged 25 years and 4 years ; were hospitalized but had uneventful recoveries. Two patients died: a 33-year-old patient who had been treated for AIDS and persistent diarrhoea and a 72-year-old patient who died 2 days after being admitted with dysentery. Of the 146 Shigella strains isolated during the surveillance period, 22 15% ; were S. flexneri and the others were S. sonnei. No S. dysenteriae or S. boydii strains were detected. Of the 22 S. flexneri isolates, the three most frequently encountered serotypes were 2a 36% ; , 1b 23% ; and 3b 28% ; . Of 124 S. sonnei isolates tested, 111 90% ; were resistant to tetracycline, 94% to co-trimoxazole trimethoprimsulfamethoxazole ; , 6% to ampicillin, and 2% to chloramphenicol. Of the S. flexneri. North India and to determine the best phenotypic technique for detection of ESBLs among the clinical isolates. Material & Methods One hundred consecutive, non-repeat clinical isolates of K. pneumoniae obtained from various clinical specimens sent to microbiology laboratory at University College of Medical Sciences and Guru Tegh Bahadur Hospital, Delhi during March and August 2001 were included in the study. The isolates were identified with standard biotyping methods 20 . Of these neonatal intensive care unit NICU ; contributed to 19 isolates, and 31 isolates each were recovered from wound swabs from burns unit, and samples from various sites in patients admitted to inpatient units. Samples from outpatients contributed 18 isolates. One isolate was recovered from a patient in ICU. Antimicrobial susceptibilities of the isolates to 20 different antimicrobial agents g ; viz. cefoperazone, 75 ; ceftazidime CAZ ; , 30 ; cefotaxime CTX ; 30 ; aztreonam ATM ; 30 ; ceftriaxone CRO ; 30 ; cefepime, 30 ; , cefoxitin 30 ; , cefotetan, 30 ; cotrimoxazole 1.25 23.75 ; amikacin, 30 ; gentamicin, 10 ; kanamycin, 30 ; ciprofloxacin, 5 ; chloramphenicol, 30 ; pipracillin, 100 ; pipracillin + tazobactam, 100 10 ; amoxycillin + clavulanate, 20 10 ; , loracarbef 30 ; imipenem 10 ; and netilmicin 30 ; were determined by standard disk diffusion SDD ; using commercially available disks Oxoid, Basingstoke, UK ; and were categorized as sensitive, intermediate and resistant as per National Committee for Clinical Laboratory Standards NCCLS ; guidelines wherever applicable1. Quality control was achieved by using standard strain of Escherichia coli ATCC 25922. NCCLS recommendations to identify potential ESBL producing isolates using standard disk diffusion technique were followed, i.e., zone sizes of 22mm, 27mm, and 25mm for CAZ, ATM, CTX and CRO respectively, were taken to identify potential ESBL harbouring isolates1. MICs of CAZ and CTX for these isolates were determined by the agar dilution and broth dilution methods using series of dilutions containing the antimicrobial CAZ or CTX ; alone final concentrations. INJECTION, PENICILLIN G BENZATHINE, UP TO 600, 000 UNITS INJECTION, PENICILLIN G BENZATHINE, UP TO 1, 200, 000 UNITS INJECTION, PENICILLIN G BENZATHINE, UP TO 2, 400, 000 UNITS BOTULINUM TOXIN TYPE A, PER UNIT BOTULINUM TOXIN TYPE B, PER 100 UNITS INJECTION, BUPRENORPHINE HYDROCHLORIDE, 0.1 MG INJECTION, EDETATE CALCIUM DISODIUM, UP TO 1000 MG INJECTION, CALCIUM GLUCONATE, PER 10 ML INJECTION, CALCIUM GLYCEROPHOSPHATE AND CALCIUM LACTATE, PER 10 ML INJECTION, CALCITONIN SALMON, UP TO 400 UNITS INJECTION, CALCITRIOL, 1 MCG AMP. INJECTION, CALCITRIOL, 0.1 MCG INJECTION, CASPOFUNGIN ACETATE, 5 MG INJECTION, LEUCOVORIN CALCIUM, PER 50 MG INJECTION, MEPIVACAINE HYDROCHLORIDE, PER 10 ML INJECTION, CEFAZOLIN SODIUM, 500 MG INJECTION, CEFEPIME HYDROCHLORIDE, 500 MG INJECTION, CEFOXITIN SODIUM, 1 GM INJECTION, CEFTRIAXONE SODIUM, PER 250 MG INJECTION, STERILE CEFUROXIME SODIUM, PER 750 MG INJECTION, CEFOTAXIME SODIUM, PER GM INJECTION, BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE, PER 3 MG INJECTION, BETAMETHASONE SODIUM PHOSPHATE, PER 4 MG INJECTION, CAFFEINE CITRATE, 5MG INJECTION, CEFTAZIDIME, PER 500 MG INJECTION, CEFTIZOXIME SODIUM, PER 500 MG INJECTION, CHLORAMPHENICOL SODIUM SUCCINATE, UP TO 1 GM INJECTION, CHORIONIC GONADOTROPIN, PER 1, 000 USP UNITS INJECTION, CLONIDINE HYDROCHLORIDE, 1 MG INJECTION, CIDOFOVIR, 375 MG INJECTION, CILASTATIN SODIUM; IMIPENEM, PER 250 MG INJECTION, CIPROFLOXACIN FOR INTRAVENOUS INFUSION, 200 MG INJECTION, CODEINE PHOSPHATE, PER 30 MG INJECTION, COLCHICINE, PER 1MG and cilexetil.
|
